CRL-8027 OKT 11雜交瘤細(xì)胞抗CD2,ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞|,細(xì)胞庫管理規(guī)范,提供的細(xì)胞株背景清楚,提供參考文獻(xiàn)和*培養(yǎng)條件
CRL-8027 OKT 11雜交瘤細(xì)胞抗CD2,ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞|,細(xì)胞庫管理規(guī)范,提供的細(xì)胞株背景清楚,提供參考文獻(xiàn)和*培養(yǎng)條件
8027 OKT 11雜交瘤細(xì)胞抗CD2 的詳細(xì)介紹
CRL-8027 OKT 11雜交瘤細(xì)胞抗CD2
ATCC? Number: | CRL-8027? | Price: | $399.00 |
Designations: | OKT 11 | Depositors: | Ortho Pharmaceutical Corporation | Isotype: | IgG1 | Biosafety Level: | 1 | Shipped: | frozen | Medium & Serum: | See Propagation | Growth Properties: | suspension | Organism: | Mus musculus (B cell); Mus musculus (myeloma) (mouse (B cell); mouse (myeloma)) | Morphology: | lymphoblast
| Source: | Cell Type: hybridoma: B lymphocyte; | Cellular Products: | immunoglobulin; monoclonal antibody; against human T cell (human T lymphocyte) and human E rosette positive thymocytes (human thymic lymphocyte); against CD2 | Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| Comments: | Mice were immunized with human T cell leukemia cells (acute lymphoblastic leukemia). Spleen cells were fused with P3X63Ag8.U1 myeloma cells. | Propagation: | ATCC complete growth medium: Iscove's modified Dulbecco's medium, 80%; fetal bovine serum, 20% | Subculturing: | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. | References: | 3507: Kung PC, Goldstein G. Monoclonal antibody to a human T cell antigen and methods of preparing same. US Patent 4,364,937 dated Dec 27 1982 |
|